Targetable ERBB2 mutations independently predict an aggressive phenotype in primary, ERBB2 non-amplified, hormone receptor positive lobular breast cancer

被引：0

作者：

Kurozumi, Sasagu ^{[1
]}

Green, Andrew R. ^{[1
]}

Ellis, Ian O. ^{[1
]}

Rakha, Emad A. ^{[1
]}

Fujii, Takaaki ^{[2
]}

Shirabe, Ken ^{[2
]}

Heery, David ^{[3
]}

Zwart, Wilbert ^{[4
]}

Oesterreich, Steffi ^{[5
,6
]}

Johnston, Simon J. ^{[1
]}

机构：

[1] Univ Nottingham, Nottingham Breast Canc Res Ctr, Nottingham, England

[2] Gunma Univ, Dept Gen Surg Sci, Grad Sch Med, Gunma, Japan

[3] Univ Nottingham, Sch Pharm, Gene Regulat Lab, Nottingham, England

[4] Netherlands Canc Inst, Amsterdam, Netherlands

[5] UPMC Hillman Canc Ctr, Womens Canc Res Ctr, Pittsburgh, PA USA

[6] Magee Women Res Inst, Pittsburgh, PA USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-P1-18-06

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1-18-06

引用

页数：2

共 50 条

[1] Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
Kurozumi, Sasagu
Alsaleem, Mansour
Monteiro, Cintia J.
Bhardwaj, Kartikeya
Joosten, Stacey E. P.
Fujii, Takaaki
Shirabe, Ken
Green, Andrew R.
Ellis, Ian O.
Rakha, Emad A.
Mongan, Nigel P.
Heery, David M.
Zwart, Wilbert
Oesterreich, Steffi
Johnston, Simon J.
BREAST CANCER RESEARCH, 2020, 22 (01)
[2] Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
Sasagu Kurozumi
Mansour Alsaleem
Cíntia J. Monteiro
Kartikeya Bhardwaj
Stacey E. P. Joosten
Takaaki Fujii
Ken Shirabe
Andrew R. Green
Ian O. Ellis
Emad A. Rakha
Nigel P. Mongan
David M. Heery
Wilbert Zwart
Steffi Oesterreich
Simon J. Johnston
Breast Cancer Research, 22
[3] Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: Validation using a novel gene signature of HER2 activation
Alsaleem, Mansour
Kurozumi, Sasagu
Bhardwaj, Kartikeya
Monteiro, Cintia
Joosten, Stacey E. P.
Green, Andrew R.
Fujii, Takaaki
Shirabe, Ken
Ellis, Ian O.
Rakha, Emad A.
Mongan, Nigel P.
Heery, David M.
Zwart, Wilbert
Oesterreich, Steffi
Johnston, Simon J.
CANCER RESEARCH, 2021, 81 (04)
[4] Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer
Zito, Christina I.
Riches, David
Kolmakova, Julia
Simons, Jan
Egholm, Michael
Stern, David F.
GENES CHROMOSOMES & CANCER, 2008, 47 (07): : 633 - 638
[5] Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
Li, Guangyuan
Wang, Xiaoqi
Hibshoosh, Hanina
Jin, Cheng
Halmos, Balazs
PLOS ONE, 2014, 9 (09):
[6] Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
Eya Wolfson
Shira Solomon
Eran Schmukler
Yona Goldshmit
Ronit Pinkas-Kramarski
Cell Death & Disease, 9
[7] Extracellular domain ERBB2 (ERBB2 ECD+) mutations in urothelial bladder cancer (UBC).
Basin, Michael
Jacob, Joseph M.
Bratslavsky, Gennady
Grivas, Petros
Spiess, Philippe E.
Li, Roger
Necchi, Andrea
Pavlick, Dean C.
Huang, Richard S. P.
Lin, Douglas I.
Danziger, Natalie
Sokol, Ethan
Sivakumar, Smruthy
Ross, Jeffrey S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[8] Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
Wolfson, Eya
Solomon, Shira
Schmukler, Eran
Goldshmit, Yona
Pinkas-Kramarski, Ronit
CELL DEATH & DISEASE, 2018, 9
[9] A reason why the ERBB2 gene is amplified and not mutated in breast cancer
Birnbaum, Daniel
Sircoulomb, Fabrice
Imbert, Jean
CANCER CELL INTERNATIONAL, 2009, 9
[10] A reason why the ERBB2 gene is amplified and not mutated in breast cancer
Daniel Birnbaum
Fabrice Sircoulomb
Jean Imbert
Cancer Cell International, 9

← 1 2 3 4 5 →